1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial.
Saved in:
| Title: | 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. |
|---|---|
| Authors: | Solomon, B.J.1 (AUTHOR), Drilon, A.2 (AUTHOR), Lin, J.J.3 (AUTHOR), Bazhenova, L.4 (AUTHOR), Goto, K.5 (AUTHOR), De Langen, J.6 (AUTHOR), Kim, D-W.7 (AUTHOR), Wolf, J.8 (AUTHOR), Springfeld, C.9 (AUTHOR), Popat, S.10 (AUTHOR), Lim, D.W-T.11 (AUTHOR), Baik, C.S.12 (AUTHOR), Hervieu, A.13 (AUTHOR), Moreno Garcia, V.14 (AUTHOR), Yang, N.15 (AUTHOR), Thamake, S.16 (AUTHOR), Ades, F.17 (AUTHOR), Trone, D.18 (AUTHOR), Besse, B.19 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS787-S788. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
